Rani Therapeutics
RANI
42 hedge funds and large institutions have $5.23M invested in Rani Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
35% more funds holding
Funds holding: 31 → 42 (+11)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
8.71% less ownership
Funds ownership: 20.18% → 11.47% (-8.7%)
44% less call options, than puts
Call options by funds: $157K | Put options by funds: $279K
59% less capital invested
Capital invested by funds: $12.8M → $5.23M (-$7.53M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$612K |
| 2 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
+$251K |
| 3 |
Two Sigma Advisers
New York
|
+$231K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$193K |
| 5 |
IAS
Insigneo Advisory Services
Miami,
Florida
|
+$99.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$5.56M |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$536K |
| 3 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
-$101K |
| 4 |
Renaissance Technologies
New York
|
-$71.7K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$31.5K |
RANI Hedge Fund Activity: Q4 2024 in Review
42 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q4 2024, worth a combined $5.23M — down 59% from $12.8M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RANI positions and 5 closed out — a net gain of 11 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Two Sigma Investments, opening a new position worth an estimated $612K. The largest seller was Armistice Capital, exiting entirely with an estimated $5.56M sold.
- 42 institutional investors held Rani Therapeutics (RANI) as of Q4 2024, up from 31 in Q3 2024.
- Funds reported $5.23M of Rani Therapeutics stock for Q4 2024, down 59% quarter-over-quarter.
- 16 funds opened new Rani Therapeutics positions in Q4 2024 and 5 closed out, a net change of +11 holders.
- The largest Rani Therapeutics buyer in Q4 2024 was Two Sigma Investments, an estimated $612K added.
- The largest Rani Therapeutics seller in Q4 2024 was Armistice Capital, an estimated $5.56M sold.
Based on aggregated 13F filings for Q4 2024.